Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-ct119
Abstract: Background: Accumulation of extracellular adenosine in the tumor microenvironment activates A2aR suppressing anti-tumor immunity. CPI-444 is an oral, selective A2aR antagonist with single agent (SA) antitumor efficacy in mouse models, and the addition of anti-PD-1/PD-L1… read more here.
Keywords: solid tumors; advanced solid; cancer; activity ... See more keywords
A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Immunology Research"
DOI: 10.1158/2326-6066.cir-18-0056
Abstract: Adenosine signaling in tumors can lead to suppression of antitumor responses. A new adenosine receptor antagonist, CPI-444, neutralized this suppression, resulting in tumor regression and immune memory, and when combined with immune checkpoint blockade, further… read more here.
Keywords: anti ctla; anti anti; cpi; antitumor responses ... See more keywords
Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.3004
Abstract: 3004Background: Adenosine production in the tumor leads to immunosuppression through A2aR on infiltrating immune cells. CPI-444 is an oral A2aR antagonist with single agent(SA) anti-tumor activity ... read more here.
Keywords: a2ar antagonist; clinical activity; cell; safety clinical ... See more keywords